For Immediate Release
Chicago, IL – September 25, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include J&J JNJ, Pfizer PFE, AstraZeneca AZN, Sanofi SNY and GlaxoSmithKline GSK.
Here are highlights from Thursday’s Analyst Blog:
Pharma Stock Outlook: Covid-19 Phase-3 Trial Edition
J&J announced the start of a pivotal late-stage study on its potential coronavirus vaccine. Meanwhile, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency gave positive recommendations, granting marketing approval to several drugs this week.
Recap of the Week’s Most Important Stories
J&J Launches Late-Stage Studies on Coronavirus Vaccine: J&J initiated a pivotal phase III study (ENSEMBLE) on its potential COVID-19 vaccine candidate, JNJ-78436735. The study will enroll 60,000 adult participants in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the United States. The large pivotal phase III study will evaluate the safety and efficacy of a single dose of JNJ-78436735 in contrast to two doses being tested for rival vaccines of Pfizer/BioNTech, AstraZeneca /Oxford University and Moderna that are also in late-stage development. J&J expects to file for emergency use authorization of its vaccine candidate in early 2021. J&J initiated the ENSEMBLE study in collaboration with BARDA and NIAID.
FDA Grants Priority Review to Pfizer’s Xalkori sNDA: The FDA accepted Pfizer’s supplemental new drug (sNDA) seeking approval of its oncology medicine Xalkori for a new indication. The sNDA is seeking approval of Xalkori for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. With the FDA granting a priority review to the sNDA, a decision is expected in January 2021. Xalkori is presently approved to treat ALK-positive metastatic NSCLC.
Sanofi/Glaxo to Supply 300M Doses of Coronavirus Vaccine in Europe: Sanofi and GlaxoSmithKline announced an advanced purchase agreement with the European Union to supply up to 300 million doses of the COVID-19 vaccine, if approved. The vaccine is being developed by combining Sanofi’s recombinant protein-based technology with Glaxo’s pandemic adjuvant technology.
The companies also signed an agreement to supply up to 72 million doses of the vaccine to Canada, if approved.
The final decision by the European Union on these products is expected in the coming months.
The NYSE ARCA Pharmaceutical Index declined 2.9% in the last five trading sessions.
Join us on Facbook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Johnson Johnson (JNJ): Free Stock Analysis Report
Sanofi (SNY): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
